Evaluating Novel Targets & GLP-1 Combination Therapies to Improve Body Composition, Tolerability, & Longer Lasting Clinical Outcomes
The Obesity Drug Development Summit Europe is the leading industry event for experts progressing next-generation obesity therapies. This inaugural summit will convene over 50 leaders from pharma, biotech, and academia to address critical challenges like lean mass preservation, scalable manufacturing, payer-driven endpoints, and patient adherence.
Traction in the obesity space is accelerating exponentially, with countless new developments like Ascletis's ASC47, the rollout of Eli Lilly's Mounjaro in the UK, and Novo Nordisk investing $55 million in collaboration with Replicate Bioscience. Now is your time to benchmark with industry peers to secure your competitive edge and dominate the obesity market.
As the market evolves rapidly with new generics and regulatory actions, this is a vital platform to shape the future of obesity care through precision medicine and sustainable drug development.
Attending Companies Include







